2,7-dichloro-6-methyl-3-(4-methyl-piperazin-1-yl)-quinoxaline | 848837-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2,7-dichloro-6-methyl-3-(4-methyl-piperazin-1-yl)-quinoxaline
• 英文别名: 2,7-dichloro-6-methyl-3-(4-methylpiperazin-1-yl)quinoxaline
• CAS: 848837-46-7
• 化学式: C₁₄H₁₆Cl₂N₄
• 分子量: 311.214
• InChiKey: FOBCAFNHKUJDKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Quinoxaline compounds
  申请人：Edwards P. James

  公开号：US20050070527A1

  公开（公告）日：2005-03-31

  Quinoxaline compounds, compositions, methods of making them, and methods of using them in leukocyte recruitment inhibition, in modulating an H 4 receptor, and in treating conditions such as inflammation, H 4 receptor-mediated conditions, and related conditions.

  喹诺醌化合物、组合物、制备方法，以及在白细胞召集抑制、调节H4受体以及治疗炎症、H4受体介导的疾病和相关疾病中使用它们的方法。
• HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
  申请人：Borchardt Allen J.

  公开号：US20120065187A1

  公开（公告）日：2012-03-15

  The present invention relates to compounds and methods which may be useful as inhibitors of H 1 R and/or H 4 R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

  本发明涉及化合物和方法，这些化合物和方法可用作H1R和/或H4R的抑制剂，用于治疗或预防炎症、自身免疫、过敏和眼部疾病。
• QUINOXALINE COMPOUNDS
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1670774A1

  公开（公告）日：2006-06-21
• [EN] QUINOXALINE COMPOUNDS<br/>[FR] COMPOSES DE QUINOXALINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005033088A1

  公开（公告）日：2005-04-14

  Quinoxaline compounds, compositions, methods of making them, and methods of using them in leukocyte recruitment inhibition, in modulating an H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions. Formula (I): wherein B is, independently from other member and substituent assignments, N or CR7; Y is independently from other member and substituent assignments, O, S or NH; n is, independently from member and substituent assignments, 1 or 2.